ARTIVA BIOTHERAPEUTICS, INC. (ARTV)
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
📈 **POSITIVE** • Medium confidence analysis (74%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (89%) **Content type:** Clinical